Similar articles

• The duty to disclose (even more) adverse clinical trial results.

  Hassoun N. Hassoun N. Am J Bioeth. 2009 Aug;9(8):33-4. doi: 10.1080/15265160902893874. Am J Bioeth. 2009. PMID: 19998155 No abstract available.
• Disclosing clinical trial results: publicity, significance and independence.

  Liao SM, Sheehan M, Clarke S. Liao SM, et al. Am J Bioeth. 2009 Aug;9(8):W3-5. doi: 10.1080/15265160903088151. Am J Bioeth. 2009. PMID: 19998144 No abstract available.
• Disclosure of adverse clinical trial results--should legal immunity be granted to drug companies?

  Vernillo A. Vernillo A. Am J Bioeth. 2009 Aug;9(8):45-7. doi: 10.1080/15265160902939933. Am J Bioeth. 2009. PMID: 19998162 No abstract available.
• Commercialism and medicine: an overview.

  Kassirer JP. Kassirer JP. Camb Q Healthc Ethics. 2007 Fall;16(4):377-86; discussion 439-42. doi: 10.1017/s0963180107070478. Camb Q Healthc Ethics. 2007. PMID: 18018917 Review. No abstract available.
• Structuring the review of human genetics protocols: gene localization and identification studies.

  Glass KC, Weijer C, Palmour RM, Shapiro SH, Lemmens TM, Lebacqz K. Glass KC, et al. IRB. 1996 Jul-Aug;18(4):1-9. IRB. 1996. PMID: 11654877 Review. No abstract available.